BridgeBio Pharma (BBIO) PT Raised to $79 at Jefferies After Reporting Positive Encaleret Ph2 Data
Tweet Send to a Friend
Jefferies analyst Eun Yang raised the price target on BridgeBio Pharma (NASDAQ: BBIO) to $79.00 (from $77.00) after ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
